Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
AMGEN
Scientific Title
A Phase 2 Open-Label Study to Determine the Effect of Blinatumomab on Minimal Residual Disease in Subjects With High-risk Diffuse Large B-cell Lymphoma Post-autologous Hematopoietic Stem-cell Transplantation